Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253679 · ClinicalTrials.gov registry record · Phase 2
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03253679: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT03253679 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03253679, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase II trial studies how well AZD1775 works in treating patients with solid tumors with CCNE1 amplification that have spread to other places in the body (advanced) and do not respond to treatment (refractory). AZD1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Adavosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03253679
The ClinicalTrials.gov registry entry for NCT03253679 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adavosertib is the first listed.
NCT03253679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03253679 about?
NCT03253679 is a clinical study titled "AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification". This phase II trial studies how well AZD1775 works in treating patients with solid tumors with CCNE1 amplification that have spread to other places in the body (advanced) and do not respond to treatment (refractory). AZD1775 may stop the growth of tumor cells by blocking some of the enzymes needed f...
What is the current status of trial NCT03253679?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-01-16. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT03253679?
The interventions under investigation include: Adavosertib (DRUG).
Who is sponsoring clinical trial NCT03253679?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.